FDA approves Genentech Tecentriq combo for stage III colon cancer adjuvant
Genentech said the FDA approved Tecentriq and Tecentriq Hybreza in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of a certain type of stage III colon cancer.